Loading clinical trials...
Loading clinical trials...
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vertex Pharmaceuticals Incorporated
NCT05505500 · Fluid Overload, Glomerulosclerosis, Focal Segmental, and more
NCT03949972 · Glomerulosclerosis, Focal Segmental, Minimal Change Disease, and more
NCT04235621 · Glomerulosclerosis, Focal Segmental, Minimal Change Disease, and more
NCT00098020 · Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
NCT02000440 · Glomerulosclerosis, Focal Segmental
University of Alabama at Birmingham - The Kirklin Clinic
Birmingham, Alabama
California Institute of Renal Research
San Diego, California
The George Washington University Medical Faculty Associates - Kidney Disease & Hypertension
Washington D.C., District of Columbia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions